Test Price
1,200 AED✅ Home Collection Available
NPM1 Gene Fragment Analysis in UAE | 1200 AED | 2026 DHA Guidelines
تحليل طفرة الجين NPM1 في الإمارات | 1200 درهم | معتمد من هيئة الصحة بدبي
Clinical Excellence Directly to Your Doorstep
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection through ISO Certified Cold-Chain transport, available 8 AM – 11 PM, 7 days a week.
- Clinical Guidance: Complimentary Telephonic Post-Test Interpretation by DHA-licensed experts.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
الملخص التنفيذي:
يُتيح تحليل طفرة الجين NPM1 في مختبرنا المعتمد دوليًا وفقًا لمعايير ISO 9001:2015 تشخيصًا دقيقًا لسرطان الدم النقوي الحاد ومتابعة الحد الأدنى للمرض المتبقي. نلتزم بقوانين دولة الإمارات مثل المرسوم بقانون اتحادي رقم 41 لسنة 2024 وقانون حماية بيانات المرضى، مع خدمة سحب عينات منزلية فاخرة ودعم طبي متواصل.
Overview
NPM1 Gene Fragment Analysis is a high-resolution DNA test that detects mutations in the nucleophosmin (NPM1) gene, most commonly associated with acute myeloid leukemia (AML). It provides essential prognostic information and can be used to monitor minimal residual disease (MRD) after therapy.
تحليل طفرة جين NPM1 هو اختبار جزيئي عالي الدقة للكشف عن طفرات مورّثة النيوكليوفوسمين، المرتبطة بشكل أساسي بابيضاض الدم النقوي الحاد، ويُستخدم في التنبؤ بسير المرض ومتابعة الاستجابة للعلاج.
| Feature | Our Test (DHA‑Regulated) | Closest Alternative (Standard Lab) |
|---|---|---|
| Methodology | Capillary Electrophoresis Fragment Analysis (FA‑CE) with automated allele calling | Conventional gel‑based or older Sanger sequencing (less sensitive) |
| Turnaround Time | 7–8 working days | 10–14 days |
| Sample Collection | VIP home phlebotomy (8 AM – 11 PM), ISO cold‑chain logistics | In‑clinic draw only; limited transport conditions |
| Post‑Test Support | Free telephonic clinical guidance with DHA‑licensed consultant | Report only; minimal interpretation |
Physician Insight & Safety Protocol
Dr. Prabhakar Reddy (DHA License: 61713011):
“NPM1 mutation testing is a cornerstone of AML management. However, a negative result does not rule out other hematologic malignancies and must always be interpreted alongside clinical findings and additional biomarkers. Patients should discuss all results with their treating hematologist to ensure accurate integration into their care plan.”
⚠️ Medication Safety Advisory
Do not discontinue or modify any prescribed medication (including hydroxyurea, targeted therapy, or supportive care) without consulting your supervising physician. This test provides genetic information; it does not replace ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
- Active severe infection or uncontrolled sepsis – postpone elective testing.
- Recent platelet transfusion less than 24 hours before bone marrow collection may affect cellularity.
- Known severe bleeding diathesis – requires specialist clearance for invasive sampling.
- ER Red Flags: Sudden high fever (>38.3°C), uncontrolled bleeding, or acute confusion in a known leukemia patient warrants immediate emergency care, not a scheduled blood draw.
This test requires a valid physician’s prescription. Prescriptions are not applicable for elective surgery clearance, pregnancy profiling, or travel screening. For minors, consent must adhere to CDS Law 2026 (Parent/Guardian approval). All data processed under UAE PDPL and Federal Decree‑Law No. 41 of 2024 (Art. 87).
Patient FAQ & Clinical Guidance
1. What exactly is NPM1 Gene Fragment Analysis and why is it prescribed?
Direct Answer: NPM1 Gene Fragment Analysis detects specific mutations in the NPM1 gene using high‑sensitivity capillary electrophoresis, providing critical prognostic and treatment‑response information for acute myeloid leukemia patients.
It is primarily ordered by hematologists to confirm suspected AML with normal karyotype, stratify risk, and monitor residual disease after chemotherapy.
2. How is the sample collected, and does it require hospital visit?
Direct Answer: A peripheral blood sample or bone marrow aspirate is collected via our VIP home phlebotomy service 8 AM–11 PM, transported in ISO‑certified cold‑chain conditions, eliminating the need for a clinic visit.
A physician’s prescription is mandatory; blood draws are performed by DHA‑licensed phlebotomists following strict antiseptic protocols.
3. Can an NPM1 mutation result influence my treatment decision?
Direct Answer: NPM1 mutation status directly impacts AML risk stratification and may guide the need for allogeneic stem cell transplantation or targeted maintenance therapy, making it a decisive factor in personalized care plans.
Always interpret results with your hematologist; a ‘negative’ does not exclude other actionable mutations.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians